http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
-
Soligenix, Inc. (SNGX) Reports Successful Protection from Sudan Ebolavirus with a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
-
Soligenix, Inc. (SNGX) Granted UK Pediatric Investigational Plan Waiver for HyBryte in CTCL
-
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
-
Soligenix, Inc. (SNGX) Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax Vaccine
-
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
-
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
-
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
-
Soligenix (SNGX) Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
-
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
-
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Soligenix, Inc. (SNGX) to Advance Synthetic Hypericin Development in Psoriasis
-
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
-
Soligenix, Inc. (SNGX) Active Ingredient Hypericin Granted FDA Orphan Drug Designation for Treatment of T-cell Lymphoma
-
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
-
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
-
Soligenix (SNGX) Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
-
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
-
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
-
HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting
-
Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell
-
Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter
-
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
-
Vista Partners Publishes January 2016 Newsletter
-
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
-
What $40 or Less Oil Means to the Economy
-
What Summer Downturn?
-
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
-
Should We Believe the Fed Will Not Raise Rates in 2015?
-
Vista Partners Publishes July 2015 Macroeconomic & Investment Newsletter
-
Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell
-
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
-
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
-
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
-
Vista Partners Publishes March 2015 Macroeconomic & Investment Newsletter

